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CORRECTION Open Access
Correction to: Randomized prospective
phase III trial of 68Ga-PSMA-11 PET/CT
molecular imaging for prostate cancer
salvage radiotherapy planning [PSMA-SRT]
Jeremie Calais1*, Johannes Czernin1*, Wolfgang P. Fendler1,2, David Elashoff3 and Nicholas G. Nickols4,5
Correction to: BMC Cancer
https://doi.org/10.1186/s12885-018-5200-1
Following publication of the original article [1], we
have been notified that one of the author names was
listed incorrectly. Both incorrect and correct author
names are presented below. The original publication has
been corrected.
 Originally published name:
Nicholas Nicholas G. Nickols
 Correct name:
Nicholas G. Nickols
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